Hegseth Orders Annual Testosterone Screening For Troops

SITUATION:

Defense Secretary Pete Hegseth announced a new Pentagon policy on July 15, 2026. Starting this year, every active duty and reserve service member age 30 or older must undergo annual testosterone screening as part of their standard health assessment.

Troops younger than 30 can request the test voluntarily. Hegseth, who now goes by “Secretary of War” under a title change ordered by President Trump last September, described the initiative in a video posted to social media, saying it would ensure service members have the “biological foundation” needed to fight.

The Department of Defense’s official name remains unchanged in law; Congress has not yet approved a measure to formally rename it the Department of War, though several committees have advanced the idea in the pending defense policy bill.

Hegseth stressed that any resulting treatment, including testosterone replacement therapy, would remain a personal choice. The Department of War has not released a cost estimate or timeline for the rollout. It also has not said whether female troops will get comparable hormone screening.

This is not the first standards-focused policy from Hegseth’s Pentagon. In recent months he has ordered new grooming rules limiting facial hair, mandated twice-yearly fitness tests, and rescinded the mandatory seasonal flu vaccine requirement. The policy also arrives as U.S. forces continue strikes against Iran.

THE TRUTH:

The concept behind the policy has some limited grounding in military research, but that research points in a narrower direction than the policy itself. Psychologist Chris Frueh first described “Operator Syndrome” in 2020 after observing severely depleted testosterone in special operations troops, tied to years of high-tempo deployments and repeated blast exposure. Congress requested a briefing on the phenomenon in 2024.

Army-funded studies have established that intense combat stress, including extreme physical exertion, sleep deprivation, and calorie restriction, can significantly reduce testosterone levels. That finding is well documented, particularly among special operations forces.

Evidence for the reverse claim, that artificially restoring or raising testosterone levels improves combat effectiveness, is far thinner. Small Army trials found that testosterone supplementation helped preserve muscle mass during simulated high-stress conditions, but researchers involved cautioned the studies were short in duration and too limited to justify testosterone therapy as a standard performance strategy. No research at scale supports the claim for the broader force, and the vast majority of service members covered by the new policy do not serve in the intense combat roles the existing research examined.

Medical groups have raised separate concerns about the screening itself. The American Urological Association and the Endocrine Society do not recommend routine testosterone screening in the absence of symptoms, and current FDA labeling limits testosterone replacement therapy to men with a diagnosed hormone deficiency.

The FDA proposed loosening those prescribing limits last month, a separate move by health officials to expand access to testosterone therapy nationwide. No other country’s armed forces have adopted a similar mandatory testosterone screening program.

WHY IT MATTERS:

Readiness and troop welfare are legitimate priorities, and the research behind Operator Syndrome deserves the attention Congress already gave it. The question is whether a policy built around a narrow, high-stress population, using evidence that stress lowers testosterone, justifies a much larger and unproven leap: that artificially raising testosterone levels will improve performance across a force where most troops never face that level of combat stress.

The Pentagon has not released cost or timeline figures. That silence matters given reports the department is already stretched thin on funding this year.

The absence of guidance on female service members also stands out, given that questions about parity surfaced almost immediately among lawmakers on both sides of the aisle. A policy framed around universal readiness has, so far, been built almost entirely around one half of the force.

Medical societies built their guidelines around real-world evidence, not policy memos. Whether the program improves readiness or simply adds cost to a stretched Pentagon budget remains an open question for now.

SOURCES:

• Military.com, “Hegseth Orders Mandatory Testosterone Screening, Optional TRT for Troops 30 & Older”
• Task & Purpose, “Pentagon’s testosterone program builds on ‘operator syndrome’ worries in special operations”
• Time, “What Urologists Think of the Military’s New Testosterone Testing Policy”
• PBS NewsHour, “Hegseth announces new policy to test troops for low testosterone and offer them hormone replacement therapy”
• The Center Square, “Hegseth’s ‘High-T’ troop screening mandate comes without cost estimate”
• Special Operations Association of America, “Hormone Loss in Special Operations Addressed in NDAA”
• eBioMedicine (The Lancet), “Testosterone replacement for male military personnel: A potential countermeasure to reduce injury and improve performance under extreme conditions”
• The Washington Post / Military Times / Air & Space Forces Magazine, reporting on Department of War name change status